SNDX Q2 2018 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+24.3% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$19M-5000.3% margin

Net Income

-$18M-4851.7% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$105M

Total Liabilities

$35M

Stockholders' Equity

$70M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$305,000	+24.3%
Gross Profit	$379,000	$305,000	+24.3%
Operating Income	-$19M	-$14M	-36.9%
Net Income	-$18M	-$14M	-34.8%